Isolation and characterization of the circulating truncated form of PCSK9
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Isolation and characterization of the circulating truncated form of PCSK9
Authors
Keywords
-
Journal
JOURNAL OF LIPID RESEARCH
Volume 55, Issue 7, Pages 1505-1514
Publisher
American Society for Biochemistry & Molecular Biology (ASBMB)
Online
2014-04-29
DOI
10.1194/jlr.m049346
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Furin-cleaved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Active and Modulates Low Density Lipoprotein Receptor and Serum Cholesterol Levels
- (2012) Michael T. Lipari et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response: the JUPITER Trial
- (2011) Z. Awan et al. CLINICAL CHEMISTRY
- Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population
- (2010) Qin Cui et al. ATHEROSCLEROSIS
- A Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) C-terminal Domain Antibody Antigen-binding Fragment Inhibits PCSK9 Internalization and Restores Low Density Lipoprotein Uptake
- (2010) Yan G. Ni et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- In VivoEvidence That Furin from Hepatocytes Inactivates PCSK9
- (2010) Rachid Essalmani et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Plasma Proprotein Convertase Subtilisin/Kexin Type 9: A Marker of LDL Apolipoprotein B-100 Catabolism?
- (2009) D. C. Chan et al. CLINICAL CHEMISTRY
- Genetic and Metabolic Determinants of Plasma PCSK9 Levels
- (2009) Susan G. Lakoski et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A new method for measurement of total plasma PCSK9: clinical applications
- (2009) Geneviève Dubuc et al. JOURNAL OF LIPID RESEARCH
- Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo
- (2008) Robert J. Schmidt et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment
- (2008) G. Lambert et al. CLINICAL CHEMISTRY
- Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
- (2008) Ahmed Zaid et al. HEPATOLOGY
- Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants
- (2008) Matthew J. Bottomley et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice
- (2008) Yi Luo et al. JOURNAL OF LIPID RESEARCH
- Errata.PCSK9 function and physiology: Fig. 1.
- (2008) Andrew S. Peterson et al. JOURNAL OF LIPID RESEARCH
- Plasma PCSK9 preferentially reduces liver LDL receptors in mice
- (2008) Aldo Grefhorst et al. JOURNAL OF LIPID RESEARCH
- PCSK9: a convertase that coordinates LDL catabolism
- (2008) Jay D. Horton et al. JOURNAL OF LIPID RESEARCH
- Molecular basis for LDL receptor recognition by PCSK9
- (2008) H. J. Kwon et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor
- (2008) D.-W. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now